Any point can be considered low -- even after massive gains -- provided there is plenty of upside left. That brings us to ...

Discover Axsome Therapeutics (NASDAQ:AXSM), a pioneering biopharmaceutical company dedicated to creating innovative ...

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Genmab (GMAB – Research Report), with a price target of $25.00. The company’s shares ...

Fintel reports that on June 3, 2025, Oppenheimer initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Outperform ...

Midtown’s best buildings are signed for. Now, even second- and third-rate offices are fast disappearing from the market, as 5 ...

Purohit’s continued optimism is primarily driven by the strong commercial performance of Auvelity, the company’s treatment ...

Discover who owns Axsome Therapeutics Inc, including major AXSM shareholders and institutional investors. Investing.com - Financial Markets Worldwide Open in App ...